Venmax Drugs — 360° view

Venmax Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹5.28 crore and net profit of ₹0.12 crore for the September 2026 quarter.

Venmax Drugs (BSE: VENMAX) closed at ₹12.20 on 20 Nov 2026, down 58.4% over the past year. Its market capitalisation is ₹18 crore and it trades at 46.5 times earnings.

Share price
₹12.20 (20 Nov 2026)
Market cap
₹18 Cr (20 Nov 2026)
P/E
46.49 (20 Nov 2026)
Revenue
₹5 Cr (September 2026 quarter)
Net profit
₹0 Cr (September 2026 quarter)
ROCE
2.96% (FY26)
ROE
2.70% (FY26)
Book value
₹12.9 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹31.49 / ₹11.11 (20 Nov 2026)
1-year return
-58.4% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: VENMAX

Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.